Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 GlaxoSmithKline | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

GlaxoSmithKline

Avandia losses, plus generics put a drain on revenues.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

GlaxoSmithKline 3Q10

3Q10 Revenues: $10.6 billion (-2%)

3Q10 Earnings: $2.1 billion (-2%)

YTD Revenues: $32.6 billion (+4%)

YTD Earnings: $3.8 billion (-38%)

Comments: Avandia sales for the quarter dropped 65% to $111 million, and will become negligible after 4Q10, a result of severe restrictions in the U.S. and withdrawal in Europe. For the year, U.S. pharma revenues have dropped 7% to $8.9 billion, primarily due to Avandia, generic Valtrex, and loss of Boniva and WellButrin XL. During the same period, pharma revenues in Europe were up 3% to $7.5 billion, while Emerging Markets were up 24% to $4.0 billion. Vaccine sales for the year were up 19% to $1.5 billion, with strong growth from Synflorix, Cervarix and Boostrix.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters